A Systematic Review and Methodological Evaluation of Published Cost-Effectiveness Analyses of Aromatase Inhibitors versus Tamoxifen in Early Stage Breast Cancer

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  John Baptiste, Ava A ^a,b,c,d,e   Wu, Wei ^a   Rochon, Paula ^a,e,f   Anderson, Geoffrey M ^a,e,f   Bell, Chaim M ^e,f,g  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c Pharmacoeconomics Research Unit   (Canada)

^d Canadian Centre for Applied Research in Cancer Control (ARCC)   (Canada)

^e INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; EARLY CANCER; ENDOMETRIUM CANCER; HUMAN; OVERALL SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW; THROMBOEMBOLISM;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84877092611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062614     Document Type: Article

References (65)

1. Smith TJ, Hillner BE, (2011) Bending the Cost Curve in Cancer Care. New Engl J Med 364: 2060-2065.
2. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, et al. (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12: 933-980.
3. Drummond M, O'Brien B, Stoddart GL, Torrance GW (2005) Methods for the Economic Evaluation of Health Care Programmes. New York: Oxford University Press Inc. 379 p.
4. Laupacis A, Feeny D, Detsky AS, Tugwell PX, (1992) How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 146: 473-481.
5. Shiroiwa T, Sung Y-K, Fukuda T, Lang H-C, Bae S-C, et al. (2010) International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 19: 422-437.
6. Neumann PJ, Goldie SJ, Weinstein MC, (2000) Preference-based measures in economic evaluation in health care. Annu Rev Public Health 21: 587-611.
7. Torrance GW, (1987) Utility approach to measuring health-related quality of life. J Chron Dis 40: 593-603.
8. Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, et al. (2012) Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2. Med Decis Making 32: 678-689.
9. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, et al. (2012) Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6. Med Decis Making 32: 722-732.
10. ATAC Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9: 45-53.
11. BIG 1-98 Collaborative Group, Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thurlimann B, et al (2009) Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. New Engl J Med 361: 766-776.
12. Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A, (2011) Toxicity of Adjuvant Endocrine Therapy in Postmenopausal Breast Cancer Patients: A Systematic Review and Meta-analysis. J Natl Cancer I 103: 1299-1309.
13. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, et al. (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28: 509-518.
14. Pezo RC, Seruga B, Krzyzanowska MK, Bedard P (2011) Quality of safety reporting in oncology-randomized controlled trials (RCTs). J Clin Oncol 29.
15. Neuner JM, Yen TW, Sparapani RA, Laud PW, Nattinger AB, (2011) Fracture risk and adjuvant hormonal therapy among a population-based cohort of older female breast cancer patients. Osteoporosis Int 22: 2847-2855.
16. Rabaglio M, Sun Z, Price KN, Castiglione-Gertsch M, Hawle H, et al. (2009) Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Ann Oncol 20: 1489-1498.
17. Seruga B, Ocana A, Niraula S, Amir E (2010) Absolute benefits of aromatase inhibitors in adjuvant treatment of breast cancer: should we know more? J Clin Oncol 28: e346-347; author reply e348.
18. Seruga B, Tannock IF, (2009) Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol 27: 840-842.
19. Google Translate API. Available: http://www.webcitation.org/5z1B8xoUj. Accessed 2013 Apr 8.
20. Neumann PJ, Stone PW, Chapman RH, Sandberg EA, Bell CM, (2000) The quality of reporting in published cost-utility analyses, 1976-1997.[see comment]. Ann Intern Med 132: 964-972.
21. International Bank for Reconstruction and Development/The World Bank (2008) Global Purchasing Power Parities and Real Expenditures- 2005 International Comparison Program. Available: http://siteresources.worldbank.org/ICPINT/Resources/icp-final.pdf. Accessed 2013 Apr 8.
22. The World Bank (2005) International Comparison Program. Available: http://data.worldbank.org/data-catalog. Accessed 2013 Apr 8.
23. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, et al. (2009) Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 19: 245-253.
24. Sroczynski G, Esteban E, Conrads-Frank A, Schwarzer R, Muhlberger N, et al. (2010) Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 17: 34-50.
25. Bureau of Labor Statistics: United States Department of Labor. (2010) CPI for All Urban Consumers (CPI-U) 1982-84 = 100 (Unadjusted)- CUUR0000SA0. Available: http://146.142.4.24/cgi-bin/surveymost?bls Accessed 2013 Apr 8.
26. Jain R, Grabner M, Onukwugha E, (2011) Sensitivity analysis in cost-effectiveness studies: from guidelines to practice. Pharmacoeconomics 29: 297-314.
27. Briggs AH, Gray AM, (1999) Handling uncertainty in economic evaluations of healthcare interventions. Brit Med J 319: 635-638.
28. Coyle D, Cranney A, Lee KM, Welch V, Tugwell P, (2001) Cost effectiveness of nasal calcitonin in postmenopausal women: use of Cochrane Collaboration methods for meta-analysis within economic evaluation. Pharmacoeconomics 19: 565-575.
29. Sculpher M, (2008) Subgroups and heterogeneity in cost-effectiveness analysis. Pharmacoeconomics 26: 799-806.
30. Ginnelly L, Claxton K, Sculpher MJ, Golder S, (2005) Using value of information analysis to inform publicly funded research priorities. Appl Health Econ Health Policy 4: 37-46.
31. Haentjens P, Magaziner J, Colon-Emeric CS, Vanderschueren D, Milisen K, et al. (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152: 380-390.
32. Delea TE, El-Ouagari K, Karnon J, Sofrygin O, Delea TE, et al. (2008) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Breast Cancer Res Treat 108: 375-387.
33. Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, et al. (2007) Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 7: 608-618.
34. Fonseca M, Araujo GT, Saad ED, Fonseca M, Araujo GTB, et al. (2009) Cost-effectiveness of anastrozole, in comparison with tamoxifen, in the adjuvant treatment of early breast cancer in Brazil. Rev Assoc Med Bras 55: 410-415.
35. Gamboa O, Diaz S, Chicaiza L, Garcia M, (2010) [Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer]. [Spanish]. Biomedica 30: 46-55.
36. Gil JM, Rubio-Terres C, Del Castillo A, Gonzalez P, Canorea F, et al. (2006) Pharmacoeconomic analysis of adjuvant therapy with exemestane, anastrozole, letrozole or tamoxifen in postmenopausal women with operable and estrogen receptor-positive breast cancer. Clini Trans Oncol 8: 339-348.
37. Hillner BE, (2004) Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer. Cancer 101: 1311-1322.
38. Hind D, Ward S, De Nigris E, Simpson E, Carroll C, et al. (2007) Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 11: iii-iv.
39. Karnon J, Delea T, Barghout V, Karnon J, Delea T, et al. (2008) Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 9: 171-183.
40. Lazzaro C, (2007) Cost-utility analysis of anastrozole versus tamoxifen for adjuvant treatment in postmenopausal women with early breast cancer. [Italian]. PharmacoEconomics- Italian Research Articles 9: 31-43.
41. Lee HJ, Lee TJ, Yang BM, Min J, (2010) Cost-effectiveness analysis of adjuvant hormonal treatments for women with postmenopausal hormone-receptor positive early breast cancer in the Korean context. J Breast Canc 13: 286-298.
42. Locker GY, Mansel R, Cella D, Dobrez D, Sorensen S, et al. (2007) Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 106: 229-238.
43. Lux MP, Wockel A, Benedict A, Buchholz S, Kreif N, et al. (2010) Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer- a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie 33: 155-166.
44. Mansel R, Locker G, Fallowfield L, Benedict A, Jones D, et al. (2007) Cost-effectiveness analysis of anastrozole vs tamoxifen in adjuvant therapy for early stage breast cancer in the United Kingdom: the 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen alone or in combination) trial. Brit J Cancer 97: 152-161.
45. Moeremans K, Annemans L, (2006) Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial. Int J Gynecol Cancer 16Suppl 2: 576-578.
46. Rocchi A, Verma S, (2006) Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysis. Support Care Cancer 14: 917-927.
47. Sasse AD, Sasse EC, (2009) [Cost-effectiveness analysis of adjuvant anastrozol in post-menopausal women with breast cancer]. [Portuguese]. Rev Assoc Med Bras 55: 535-540.
48. Skedgel C, Rayson D, Dewar R, Younis T, Skedgel C, et al. (2007) Cost-utility of adjuvant hormone therapies with aromatase inhibitors in post-menopausal women with breast cancer: upfront anastrozole, sequential tamoxifen-exemestane and extended tamoxifen-letrozole. Breast 16: 252-261.
49. Skedgel C, Rayson D, Dewar R, Younis T, Skedgel C, et al. (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastrozole. Breast Cancer Res Treat 101: 325-333.
50. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ, (2010) When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst 102: 82-88.
51. Annemans L, Annemans L, (2008) Methodological issues in evaluating cost effectiveness of adjuvant aromatase inhibitors in early breast cancer: a need for improved modelling to aid decision making. Pharmacoeconomics 26: 409-423.
52. Jang S, Chae YK, Haddad T, Majhail NS, (2010) Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat 121: 273-279.
53. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365: 1687-1717.
54. ATAC Trialists' Group (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365: 60-62.
55. B. I. G. Collaborative Group (2009) Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer. New Engl J Med 361: 766-776.
56. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, et al. (2007) Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. J Clin Oncol 25: 486-492.
57. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, et al. (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11: 1135-1141.
58. Jassem J, (2008) Intergroup Exemestane Study mature analysis: overall survival data. Anti-Cancer Drugs 19Suppl 1: S3-7.
59. Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, et al. (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7: 991-996.
60. Chauhan D, Miners AH, Fischer AJ, (2007) Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups. Int J Technol Assess 23: 96-100.
61. Polyzos NP, Valachis A, Mauri D, Ioannidis JP, (2011) Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test. Can Med Assoc J 183: E337-343.
62. Bell CM, Urbach DR, Ray JG, Bayoumi A, Rosen AB, et al. (2006) Bias in published cost effectiveness studies: systematic review. Brit Med J 332: 699-703.
63. Garattini L, Koleva D, Casadei G, (2010) Modeling in pharmacoeconomic studies: funding sources and outcomes. Int J Technol Assess 26: 330-333.
64. John-Baptiste A, Bell C, (2011) Industry sponsored bias in cost effectiveness analyses. Brit Med J 341: c5350.
65. John-Baptiste AA, Bell C, (2011) A glimpse into the black box of cost-effectiveness analyses. Can Med Assoc J 183: E307-308.